Literature DB >> 12841361

Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.

Michal Chmielewski1, Elzbieta Sucajtys, Julian Swierczynski, Boleslaw Rutkowski, Wojciech Bogusławski.   

Abstract

The aim of the present study was to examine hypothesis that the enhanced cholesterologenesis, found in rats with experimental chronic renal failure (CRF) resulted from the increased gene expression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase--the rate limiting enzyme in the cholesterologenesis pathway, responsible for mevalonate synthesis. Wistar rats were used and experimental CRF was achieved by 5/6 nephrectomy model. We examined: (a) the changes in the rat liver microsomal HMG-CoA reductase activity, (b) the rat liver HMG-CoA reductase mRNA abundance in various times of day. Obtained data indicates that the increased activity of HMG-CoA reductase in the liver of rats with experimental CRF parallel enhanced mRNA level and suggests that enhanced cholesterol biosynthesis, observed in experimental CRF is at least in part due to the increased HMG-CoA reductase gene expression. The results also indicate that the physiological diurnal rhythm of HMG-CoA reductase activity is preserved in the course of experimental CRF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841361

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  15 in total

1.  The mevalonate pathway and renal diseases: experimental and clinical implications.

Authors:  A Scoppola; P Galiano
Journal:  Int J Artif Organs       Date:  1998-05       Impact factor: 1.595

2.  Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts.

Authors:  D J Shapiro; J L Nordstrom; J J Mitschelen; V W Rodwell; R T Schimke
Journal:  Biochim Biophys Acta       Date:  1974-12-29

3.  Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rats with subtotal nephrectomy.

Authors:  W M Pandak; Z R Vlahcevic; D M Heuman; R J Krieg; J D Hanna; J C Chan
Journal:  Kidney Int       Date:  1994-08       Impact factor: 10.612

4.  Low leptin mRNA level in adipose tissue and normoleptinemia in experimental chronic renal failure.

Authors:  J Swierczynski; J Korczynska; M Szolkiewicz; J Karbowska; Z Kochan; T Nieweglowski; E Kusiak; B Rutkowski
Journal:  Exp Nephrol       Date:  2001

5.  Plasma mevalonate concentrations in uremic patients.

Authors:  A Scoppola; P De Paolis; G Menzinger; A Lala; S Di Giulio
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

6.  Mechanisms of malnutrition in uremia.

Authors:  G Guarnieri; G Toigo; N Fiotti; B Ciocchi; R Situlin; C Giansante; A Vasile; M Carraro; L Faccini; G Biolo
Journal:  Kidney Int Suppl       Date:  1997-11       Impact factor: 10.545

Review 7.  Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.

Authors:  P O Attman; P Alaupovic; O Samuelsson
Journal:  Kidney Int Suppl       Date:  1999-07       Impact factor: 10.545

8.  Metabolism of plasma mevalonate in rats and humans.

Authors:  R R Kopito; S B Weinstock; L E Freed; D M Murray; H Brunengraber
Journal:  J Lipid Res       Date:  1982-05       Impact factor: 5.922

9.  Diurnal rhythm of rat liver mRNAs encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase. Correlation of functional and total mRNA levels with enzyme activity and protein.

Authors:  C F Clarke; A M Fogelman; P A Edwards
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

10.  Plasma mevalonate as a measure of cholesterol synthesis in man.

Authors:  T S Parker; D J McNamara; C D Brown; R Kolb; E H Ahrens; A W Alberts; J Tobert; J Chen; P J De Schepper
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

View more
  3 in total

1.  Disorders of lipid metabolism and chronic kidney disease in the elderly.

Authors:  Devasmita Choudhury; Meryem Tuncel; Moshe Levi
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

2.  Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.

Authors:  Ana Carolina P Souza; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Yuning G Huang; Kenneth J Wilkins; Xuzhen Hu; Jonathan M Street; Alejandro Alvarez-Prats; Adam E Mullick; Amy P Patterson; Alan T Remaley; Thomas L Eggerman; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2016-04       Impact factor: 10.612

3.  Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.

Authors:  Elzbieta Sucajtys-Szulc; Marek Szolkiewicz; Julian Swierczynski; Boleslaw Rutkowski
Journal:  Mol Cell Biochem       Date:  2015-10-19       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.